Inflammatory Bowel Disease Disability Index is a valid and reliable measure of disability in an English-speaking hospital practice and predicts long-term requirement for treatment escalation

IF 2.4 Q3 GASTROENTEROLOGY & HEPATOLOGY Frontline Gastroenterology Pub Date : 2023-11-10 DOI:10.1136/flgastro-2023-102428
Darragh Storan, Edel McDermott, Jenny Moloney, Lisa Keenan, Roisin Stack, Juliette Sheridan, Glen Doherty, Garret Cullen, Louise McHugh, Hugh E Mulcahy
{"title":"Inflammatory Bowel Disease Disability Index is a valid and reliable measure of disability in an English-speaking hospital practice and predicts long-term requirement for treatment escalation","authors":"Darragh Storan, Edel McDermott, Jenny Moloney, Lisa Keenan, Roisin Stack, Juliette Sheridan, Glen Doherty, Garret Cullen, Louise McHugh, Hugh E Mulcahy","doi":"10.1136/flgastro-2023-102428","DOIUrl":null,"url":null,"abstract":"Objective The Inflammatory Bowel Disease Disability Index (IBD-DI) was developed according to WHO standards and has been validated in population-based cohorts. However, there are limited data on its relationship to various psychosocial and economic variables or its relevance to hospital clinical practice. The study aims were to determine the validity and reliability of the IBD-DI in an English-speaking hospital out-patient population and to evaluate its association with short and long-term disease activity. Design/Methods 329 subjects were enrolled in a cross-sectional and longitudinal study assessing the IBD-DI and a range of quality of life, work impairment, depression, anxiety, body image, interpersonal, self-esteem, disease activity, symptom scoring scales in addition to long-term outcome. Results The IBD-DI had adequate structure, was internally consistent and demonstrated convergent and predictive validity and was reliable in test–retest study. Disability was related to female sex (p=0.002), antidepressant use (p<0.001), steroid use (p<0.001) and disease activity (p<0.001). Higher IBD-DI scores were associated with long-term disease activity and need for treatment escalation in univariate (p<0.001) and multivariate (p=0.002) analyses. Conclusion The IBD-DI is a valid and reliable measure of disability in English-speaking hospital populations and predicts long-term requirement for treatment escalation.","PeriodicalId":46937,"journal":{"name":"Frontline Gastroenterology","volume":" 16","pages":"0"},"PeriodicalIF":2.4000,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontline Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/flgastro-2023-102428","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective The Inflammatory Bowel Disease Disability Index (IBD-DI) was developed according to WHO standards and has been validated in population-based cohorts. However, there are limited data on its relationship to various psychosocial and economic variables or its relevance to hospital clinical practice. The study aims were to determine the validity and reliability of the IBD-DI in an English-speaking hospital out-patient population and to evaluate its association with short and long-term disease activity. Design/Methods 329 subjects were enrolled in a cross-sectional and longitudinal study assessing the IBD-DI and a range of quality of life, work impairment, depression, anxiety, body image, interpersonal, self-esteem, disease activity, symptom scoring scales in addition to long-term outcome. Results The IBD-DI had adequate structure, was internally consistent and demonstrated convergent and predictive validity and was reliable in test–retest study. Disability was related to female sex (p=0.002), antidepressant use (p<0.001), steroid use (p<0.001) and disease activity (p<0.001). Higher IBD-DI scores were associated with long-term disease activity and need for treatment escalation in univariate (p<0.001) and multivariate (p=0.002) analyses. Conclusion The IBD-DI is a valid and reliable measure of disability in English-speaking hospital populations and predicts long-term requirement for treatment escalation.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
炎症性肠病失能指数是英语医院实践中有效和可靠的失能指标,并预测治疗升级的长期需求
炎症性肠病失能指数(IBD-DI)是根据世卫组织标准制定的,并已在基于人群的队列中得到验证。然而,关于其与各种社会心理和经济变量的关系或其与医院临床实践的相关性的数据有限。本研究的目的是确定IBD-DI在英语医院门诊人群中的有效性和可靠性,并评估其与短期和长期疾病活动的关系。设计/方法329名受试者参加了一项横断面和纵向研究,评估IBD-DI和一系列生活质量、工作障碍、抑郁、焦虑、身体形象、人际关系、自尊、疾病活动、症状评分量表以及长期结果。结果IBD-DI结构合理,内部一致,具有收敛效度和预测效度,在重测研究中可靠。残疾与女性性别(p=0.002)、抗抑郁药使用(p= 0.001)、类固醇使用(p= 0.001)和疾病活动性(p= 0.001)有关。在单变量分析(p= 0.001)和多变量分析(p=0.002)中,较高的IBD-DI评分与长期疾病活动性和需要升级治疗相关。结论IBD-DI在英语医院人群中是一种有效、可靠的残疾测量方法,可以预测治疗升级的长期需求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Frontline Gastroenterology
Frontline Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
4.70
自引率
11.50%
发文量
93
期刊介绍: Frontline Gastroenterology publishes articles that accelerate adoption of innovative and best practice in the fields of gastroenterology and hepatology. Frontline Gastroenterology is especially interested in articles on multidisciplinary research and care, focusing on both retrospective assessments of novel models of care as well as putative future directions of best practice. Specifically Frontline Gastroenterology publishes articles in the domains of clinical quality, patient experience, service provision and medical education.
期刊最新文献
Neuroendocrine tumours found at endoscopy: diagnosis and staging British Society of Gastroenterology Endoscopic Retrograde Cholangiopancreatography (ERCP) Quality Improvement Programme: minimum service standards and good practice statements Investigation of abnormal liver blood tests in patients with inflammatory bowel disease Effectiveness of risankizumab induction and maintenance therapy for refractory Crohn’s disease: a real-world experience from a preapproval access programme and early access to medicines scheme #FGDebate: addressing regional variations in care and outcomes for patients with liver disease
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1